It has been a stellar 18 months for Nami Surgical — from closing our first $4.3 million investment round in April 2024 to bringing in world-class expertise to our team and board of directors. These milestones have propelled us from strength to strength, allowing us to further develop and demonstrate our patented technology — innovation set to revolutionise the robotic-assisted surgery market in the coming years.

Now, with market interest accelerating and clinical demand at an all-time high, we are launching our next fundraising campaign to scale globally, advance our unique technology, and expand our product pipeline to meet urgent clinical needs

Our Technology: The world-first miniaturised ultrasonic scalpel designed to bridge the integration gap in robotic surgery.

Nami’s miniaturised ultrasonic scalpels are set to redefine what’s possible in robotic-assisted surgery.

Today, conventional ultrasonic scalpels are indispensable for dissecting and simultaneously cauterising soft tissue, while sealing medium to large blood vessels in laparoscopic minimally invasive procedures. Yet their size has prevented their integration into the advanced-energy portfolios of robotic systems, as they cannot be integrated with wristed robotic joints. This is the main technological barrier preventing ultrasonic technology from being part of the robotic surgeon’s toolbox — a limitation that robot manufacturers want solved, and surgeons are eager to overcome to improve millions of procedures each year.

At Nami Surgical, we have solved this. Our miniaturised ultrasonic scalpel integrates seamlessly with a wristed robotic joint, passes through standard 8mm surgical ports, and is fully articulated within the body — enabling surgeons to perform robotic procedures faster, more safely, and with greater precision.

Over the past 18 months, Nami has also engineered a fully modular, smart ultrasonic driving system that precisely controls energy delivery to the surgical site. This represents a major technical milestone, achieved by our talented team in record time. Clinical testing has demonstrated performance on par with market-leading devices—despite Nami’s patent-protected technology being more than 90% smaller than current commercial solutions.

A Multi-Billion Dollar Market on the Verge of Transformation

Over 2 million robotic-assisted procedures were performed in 2024 alone, and adoption is rapidly accelerating.

In the UK, the NHS has set a bold target: increasing robot-assisted keyhole operations from 70,000 to 500,000 annually by 2035, with nine out of ten keyhole surgeries expected to be robot-assisted.

Globally, the surgical robotics market was valued at over USD 8 billion in 2024 and is projected to exceed USD 30 billion by 2035 — an average CAGR of 14% across major forecasts. Growth is being driven by rapid adoption in North America, Europe, the UK, and Asia, alongside accelerating healthcare investments and regulatory approvals.

In this market, over 50% of recurring revenue for medical robotics companies comes from the sale of surgical instruments and accessories — creating a high-margin, long-term revenue stream driven by adoption and procedures.

For patients, robotic-assisted surgery offers less pain, faster recovery, and fewer post-operative complications. For hospitals, it means higher procedural precision, shorter operating times, and the ability to attract and handle more complex cases.

$10 Million Raise to Accelerate with Market Demand

We are raising $10 million by December 2025 and seeking partnerships with investors who have a strong focus on surgical robotics and medical device hardware, coupled with the expertise and ambition to scale this unique opportunity globally.

The proceeds from this round will enable us to advance our technology in response to growing market interest, while leveraging strategic networks to accelerate our path to market and achieve key commercial milestones. The round, which opened in July 2025, has already secured the continued support of our existing investors.

The proceeds from this round will accelerate Nami’s growth and position the company to capture a significant share of the fast-expanding surgical robotics market by delivering on key inflection points:

• Launch a market-ready platform by advancing our soft-tissue robotic-assisted surgical technologies and cementing our lead in miniaturised ultrasonic innovation.
• Scale R&D capacity to enable high-volume prototyping and rapid testing, shortening development cycles.
• Unlock new high-value applications in bone-tissue surgery — a market where precision, control, and tissue selectivity are critical.
• Expand our leadership team to accelerate global commercialisation, strategic partnerships, and long-term stakeholder value.

“We are now fully focused on our Series A round—an important and defining moment for our team. This funding will unlock an exciting phase of commercial partnerships and shape what’s possible for our ultrasonic platform across multiple verticals. It will allow us to expand our capabilities, strengthen our already exceptional team, and move decisively toward our goal of bringing Nami’s core technology into operating rooms globally.”

Dr Nico Fenu, Co-founder and CEO

If you are an investor with proven expertise in the robotic-assisted surgical sector, we welcome the opportunity to explore how we can

partner and shape the future of surgery together.

Please contact Dr Nico Fenu at nico.fenu@namisurgical.com to express your interest.